Meghan J. Mooradian - Concepedia

Author

Meghan J. Mooradian

Also Known As

Ian A. Strohbhen, M J Mooradian, M. Mooradian, M.J. Mooradian, MEGHAN J. MOORADIAN, Meghan J Mooradian, Meghan J. Mooradian, Meghan Mooradian, Yiqin Zuo

120

Publications

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Vanderbilt University Medical Center

About

Meghan J. Mooradian is an author at Massachusetts General Hospital specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	977
2	Epidemiology	2	2	216
3	Health Sciences	1	1	15
4	Allergy	1	1	14
5	Cell Biology	1	1	11

Meghan J. Mooradian

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
The Effect of Advances in Lung-Cancer Treatment on Population Mortality Nadia Howlader, Gonçalo Forjaz, Meghan J. Mooradian, New England Journal of Medicine	2020	1.7K
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors Harish Seethapathy, Sophia Zhao, Donald F. Chute, Clinical Journal of the American Society of Nephrology	2019	291
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Divyanshu Dubey, William S. David, Kerry L. Reynolds, Annals of Neurology Timely ManagementDisease ProgressionSevere Neurological ToxicityImmunodeficienciesImmunology	2020	229
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors Amanda C. Guidon, Leeann B Burton, Bart K. Chwalisz, Journal for ImmunoTherapy of Cancer ImmunodeficienciesImmunologyPathologyConsensus Disease DefinitionsImmunotherapy	2021	197
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies Divyanshu Dubey, William S. David, Anthony A. Amato, Neurology ImmunologyPathologyInflammatory Neuropathy CauseImmunotherapyNeuroinflammation	2019	162
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Nature	2024	117
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50% Justin F. Gainor, Hira Rizvi, Esther Aguilar, Annals of Oncology	2020	114
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience Meghan J. Mooradian, Mazen Nasrallah, Justin F. Gainor, Seminars in Arthritis and Rheumatism Rheumatoid DisorderRheumatologyVasculitisAutoimmune DiseaseLupus	2018	100
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study Sara Valpione, Matteo S. Carlino, Johanna Mangana, European Journal of Cancer	2018	91
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study Bruce C. Tiu, Leyre Zubiri, James Iheke, Journal for ImmunoTherapy of Cancer	2022	82

Page 1